Drug intelligence / Profile preview

YN014

Development stage: Preclinical
Lead developer: Guangzhou Yinnuo Pharmaceutical

Overview

YN014 is an investigational drug candidate being developed by Guangzhou Yinnuo Pharmaceutical (also known as Innogen Pharmaceutical) for the treatment of Alzheimer's disease (AD). The drug is designed to act on beta-cell protective signaling pathways, a therapeutic strategy that explores the link between metabolic regulation and neuroprotection. As of early 2025, YN014 has completed all preclinical studies. The developer is currently preparing for an Investigational New Drug (IND) submission in China in 2025 and plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2026.

Beyond the preview

Go deeper on YN014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YN014.

Explore the full profile